甲氨蝶呤联合来氟米特治疗类风湿关节炎40例疗效观察  

Observation on the efficacy of methotrexate combined with leflunomide in the treatment of 40 cases of rheumatoid arthritis

作　　者：崔佳佳 胡怀霞[1] 李慧 王田玲 于秀娟[1] CUI Jia-jia;HU Huai-xia;LI Hui(Department of Rheumatism Immunology, Lianyungang Second People’s Hospital, Lianyungang 222000, China)

机构地区：[1]连云港市第二人民医院风湿免疫科

出　　处：《中国现代药物应用》2019年第11期95-97,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨甲氨蝶呤联合来氟米特治疗类风湿关节炎的临床疗效。方法 80例类风湿关节炎患者,随机分为观察组和对照组,每组40例。观察组患者采用甲氨蝶呤联合来氟米特治疗,对照组患者采用甲氨蝶呤联合羟氯喹治疗。观察比较两组患者的治疗效果,治疗前后C反应蛋白(CRP)、类风湿因子(RF)及抗环瓜氨酸肽抗体(ACCP)水平。结果治疗3个月后,观察组患者的总有效率为95.0%,明显高于对照组的80.0%,差异有统计学意义(χ^2=4.1143, P=0.0425<0.05)。两组患者治疗前CRP、RF及ACCP水平比较差异均无统计学意义(P>0.05)。两组患者治疗3个月后的CRP、RF及ACCP水平均明显低于治疗前,且观察组CRP、RF及ACCP水平分别为(7.5±4.4)mg/L、(27.1±12.9)IU/ml、(27.1±14.9)AU/ml,均明显低于对照组的(13.1±5.8)mg/L、(36.1±11.6)IU/ml、(36.1±14.2)AU/ml,差异均有统计学意义(P<0.05)。结论对类风湿关节炎患者实施甲氨蝶呤联合来氟米特治疗的效果显著,能够有效降低CRP、RF及ACCP水平,提高治疗总有效率,值得临床推广.Objective To discuss the clinical efficacy of methotrexate combined with leflunomide in the treatment of rheumatoid arthritis. Methods A total of 80 rheumatoid arthritis patients were randomly divided into observation group and control group, with 40 cases in each group. The observation group was treated with methotrexate combined with leflunomide, and the control group was treated with methotrexate combined with hydroxychloroquine. Observation and comparison were made on treatment effect, C-reactive protein (CRP), rheumatoid factor (RF) and anti-cyclic citrullinated peptide (ACCP) before and after treatment between the two groups. Results After 3 months of treatment, the observation group had obviously higher total effective rate as 95.0% than 80.0% in the control group, and the difference was statistically significant (χ^2=4.1143, P=0.0425<0.05). Both groups had no statistically significant difference in CRP, RF and ACCP before treatment (P>0.05). Both groups had obviously lower CRP, RF and ACCP after 3 months of treatment than those before treatment, and the observation group had obviously lower CRP, RF and ACCP respectively as (7.5±4.4) mg/L,(27.1±12.9) IU/ml and (27.1±14.9) AU/ml than (13.1±5.8) mg/L,(36.1±11.6) IU/ml and (36.1±14.2) AU/ml in the control group. Their difference was statistically significant (P<0.05). Conclusion Methotrexate combined with leflunomide shows remarkable effect for patients with rheumatoid arthritis. It can effectively reduce the levels of CRP, RF and ACCP, and improve the total treatment effective rate. It is worthy of clinical promotion.

关 键 词：甲氨蝶呤 来氟米特 类风湿关节炎 

分 类 号：R593.22[医药卫生—内科学]